Alliqua enters into distribution agreement with Carolon Health Care Products

Sep 26 2013

Alliqua Inc. (OTCQB: ALQA) ("Alliqua" or "the Company"), a biomedical company offering a suite of drug delivery technologies and wound healing solutions, has entered into an agreement with Carolon Health Care Products through which it will gain both new sales distribution pathways and established customers. As previously announced, Alliqua has also entered into an agreement to become a sales and distribution agent in the Americas for Europe's wound-healing sorbion GmbH & Co. KG ("sorbion") branded product line, including sorbion's sachet S wound products that Carolon has been selling. Access to the distribution network, customers and sales force provided by the Carolon agreement will be leveraged to sell the sorbion products as well as the Company's hydrogel product line, which is sold under the SilverSeal^® and Hydress^® brands.

Highlights:

• Alliqua becomes exclusive sales agent of sorbion-branded products in the Americas

• Gains access to Carolon's established distribution relationships with major wholesalers and healthcare facilities in the wound healing industry

• Obtains contract opportunities with experienced wound-sales force, thereby adding strength and reach to Alliqua's existing team

• Sales force may now also represent and sell Alliqua's 510(k) FDA-approved hydrogel products for wound care (marketed under the SilverSeal and Hydress brands) through the expanded distribution channels

• Alliqua significantly enhances potential sales footprint for future product line acquisitions and partnerships

Expressing his enthusiasm for these new agreements, David Johnson, Chief Executive Officer of Alliqua, said, "This deal with Carolon, which comes at the heels of our recently announced distribution agreement with sorbion, gives Alliqua a terrific boost for launching sorbion sana into the U.S. market, while we take over the sales of sorbion sachet S, immediately. Our existing sales capacity for our hydrogel products is now significantly expanded as well."

Johnson further elaborated: "With an already established list of sorbion customers obtained via this Carolon agreement, obtaining exclusive rights in the U.S. to other sorbion products became the next logical step in our plan to unfold a dynamic sales and distribution network in the Americas for wound care products. Every step of the way, we are committed to excellence, a seamless transition for current and future customers, excellent customer service and growth, and to offering quality-established as well as new and exciting products."  

Larry Reid, President of Carolon, stated, "We are looking forward to transitioning the sorbion product line to Alliqua as we are confident that they will build upon the foundation we have created. Carolon is actively engaged in extensive research and development involving compression technology. This agreement provides the opportunity for Carolon to concentrate on its core competencies, marketing, manufacturing and introducing new advanced compression products."